Information Provided By:
Fly News Breaks for August 9, 2017
ESPR
Aug 9, 2017 | 07:11 EDT
Jefferies analyst Michael Yee last night upgraded Esperion Therapeutics to Buy from Hold and raised his price target for the shares to $85 from $55. The shares are likely "to keep grinding higher and higher" following the "new de-risking data" for the triple combination, Yee tells investors in a research note. The analyst sees potential partnership opportunities as a "big catalyst."
News For ESPR From the Last 2 Days
ESPR
Mar 28, 2024 | 10:59 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
ESPR
Mar 27, 2024 | 10:47 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here